RET and medullary thyroid gland carcinoma: A phase III, randomized, open-label trial of pralsetinib versus standard of care (vandetanib or cabozantinib) for treatment of RET-mutated MTC (AcceleRET-MTC) has been designed and the scheduled start date is January 2022 (ClinicalTrials.gov Identifier: NCT04760288).